Clinical Trial Update: PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of a PD-1 inhibitor with Clostridium butyricum for urothelial carcinoma of the bladder; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma of the Bladder

Drugs mentioned

• Clostridium butyricum (Clostridium butyricum)
• PD-1 inhibitors

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Bladder (Urothelial, Transitional Cell) Cancer | Phase 2 | Status: RECRUITING